Cytosorbents Corp CTSO Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$4.11 up $1.05, 34.31% at close Oct 16
Last close · Previous close $3.06
- Market cap
- $12.90MAt the Oct 16 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$4.11up $1.05, 34.31%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$3.06Oct 15
- Volume684.83KOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume43.61KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $2.84 to $18.00; now $4.11
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CTSO trailed the S&P 500 in all 7 periods.
| Period | CTSO and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CTSO: down 28.3% S&P 500: up 1.5% | CTSO trailed the S&P 500 by 29.8 percentage points Trailed |
| 3M | CTSO: down 44.4% S&P 500: up 1.9% | CTSO trailed the S&P 500 by 46.3 percentage points Trailed |
| YTD | CTSO: down 67.9% S&P 500: up 12.8% | CTSO trailed the S&P 500 by 80.7 percentage points Trailed |
| 1Y | CTSO: down 77.3% S&P 500: up 16.8% | CTSO trailed the S&P 500 by 94.1 percentage points Trailed |
| Long term | ||
| 3Y | CTSO: down 87.5% S&P 500: up 81.5% −50.1% vs +22.0% a year | CTSO trailed the S&P 500 by 169.0 percentage points Trailed |
| 5Y | CTSO: down 96.5% S&P 500: up 83.1% −48.8% vs +12.9% a year | CTSO trailed the S&P 500 by 179.6 percentage points Trailed |
| 10Y | CTSO: down 96.4% S&P 500: up 319.6% −28.2% vs +15.4% a year | CTSO trailed the S&P 500 by 416.0 percentage points Trailed |
$10,000 invested in CTSO 10 years ago (Oct 14, 2016) would be worth about $364 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
CTSO trailed the S&P 500 in all 7 periods.
| Period | CTSO and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CTSO: down 28.3% S&P 500: up 1.2% | CTSO trailed the S&P 500 by 29.5 percentage points Trailed |
| 3M | CTSO: down 44.4% S&P 500: up 1.7% | CTSO trailed the S&P 500 by 46.1 percentage points Trailed |
| YTD | CTSO: down 67.9% S&P 500: up 11.9% | CTSO trailed the S&P 500 by 79.8 percentage points Trailed |
| 1Y | CTSO: down 77.3% S&P 500: up 15.5% | CTSO trailed the S&P 500 by 92.8 percentage points Trailed |
| Long term | ||
| 3Y | CTSO: down 87.5% S&P 500: up 75.0% −50.1% vs +20.5% a year | CTSO trailed the S&P 500 by 162.5 percentage points Trailed |
| 5Y | CTSO: down 96.5% S&P 500: up 71.2% −48.8% vs +11.4% a year | CTSO trailed the S&P 500 by 167.7 percentage points Trailed |
| 10Y | CTSO: down 96.4% S&P 500: up 258.1% −28.2% vs +13.6% a year | CTSO trailed the S&P 500 by 354.5 percentage points Trailed |
$10,000 invested in CTSO 10 years ago (Oct 14, 2016) would be worth about $364 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$299.80
Closing high on . Now 98.6% below that record.
Split-adjusted daily closes since Jan 2, 2013.
Stock splits
2
Latest: 1-for-20 on . Share counts adjust after each split.
Both splits
- 1-for-20
- 1-for-25
Valuation
The Oct 16 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- 0.3×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - Price-to-bookPausedBook value as of Jun 30, 2026
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −70.80%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $35.81MAt the Oct 16 close
What it would cost to buy the whole business: the market cap at the Oct 16 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own CTSO DCF in Excel. Value Cytosorbents with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $37.22Mup 3.1%
- Net income
- −$18.21M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $8.61M | −$2.77M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $9.15M | −$7.57M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $8.73M | −$1.48M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $9.62M | $1.95M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $9.49M | −$3.17M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $9.23M | −$5.50M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $8.86M | −$5.13M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $9.63M | −$4.42M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $43.17M | −$24.56M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $34.69M | −$32.81M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $31.08M | −$29.25M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $35.60M | −$20.72M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $37.06M | −$8.20M | Paused See the note under the price. |
Margins
- Gross 71.6%
- Operating −34.7%
- Net −48.9%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$9.14MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$9.15MLast 12 months
- Capital spending$11.00KLast 12 months
- −24.5%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $0.00Last 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $5.94MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$28.84MAs of Jun 30, 2026
- Net debt$22.90MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 0.66As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −445.1%Last 12 months
Over the last 12 months, Cytosorbents lost money: its net loss was 445.1% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −43.2%Last 12 months
Over the last 12 months, Cytosorbents’s net loss was 43.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Cytosorbents Corp
CytoSorbents Corporation, formerly MedaSorb Technologies Corporation is a development-stage therapeutic medical device company. As of December 31, 2011, the Company had developed and focuses on commercializing a blood purification technology that would be able to remove middle molecular weight toxins from circulating blood and physiologic fluids. The Company has developed two products, CytoSorb and BetaSorb utilizing its adsorbent polymer technology. These products are known medically as hemoperfusion devices. As of December 31, 2011, the Company had initiated and opened for enrollment a total of 14 hospital units to participate in its clinical study. The CytoSorb device consists of a cartridge containing adsorbent polymer beads, that are intended to remove toxins and other substances from blood and physiologic fluids. The cartridge incorporates connectors at either end of the device, which connect directly to an extra-corporeal circuit (bloodlines) on a stand alone basis.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- New Jersey, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
CTSO news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CTSO stock FAQ
What is CTSO stock’s price today?
Cytosorbents (CTSO) traded at $4.11 at the close on , up $1.05 (34.31%) from the previous close of $3.06. Over the past 52 weeks it has traded between $2.84 and $18.00.
If you invested $1,000 in CTSO 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CTSO on would be worth about $36 at the close on , a total return of −96.4%. The same $1,000 would be worth $35 if invested five years ago and $227 if invested one year ago. Past performance doesn’t predict future returns.
What is Cytosorbents’s market cap?
Cytosorbents’s market capitalization is about $12.9 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $4.11 (how market cap works).
How much revenue does Cytosorbents make?
Cytosorbents reported $37.2 million of revenue over the four quarters to , up 3.1% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $9.6 million, up 0.2% from a year earlier.
Is Cytosorbents profitable?
Not over the four quarters to . Cytosorbents reported a net loss of $18.2 million across those four quarters on $37.2 million of revenue.
Does CTSO pay a dividend?
Cytosorbents hasn’t paid a dividend in the last twelve months.
What is CTSO’s 52-week high and low?
Over the past 52 weeks CTSO has traded as low as $2.84 and as high as $18.00. At $4.11 at the close on , it is 77.2% below that high and 44.7% above the low.
What is CTSO’s all-time high?
CTSO’s highest closing price was $299.80 on , adjusted for stock splits. At $4.11 at the close on , it is 98.6% below that record.
Has CTSO stock ever split?
Yes, twice: 1-for-25 on ; 1-for-20 on .
How has CTSO stock performed?
Including dividends and measured to the close on , CTSO has returned −67.9% so far this year and −77.3% over the past year, and −96.5% over five years (−48.8% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Cytosorbents in?
Cytosorbents is in the Healthcare sector and the Medical Devices industry, and is headquartered in New Jersey, USA.
What exchange does CTSO trade on?
Cytosorbents trades on the Nasdaq under the ticker symbol CTSO. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.